Patients With MDR P. Aeruginosa Bacteremia Or Pneumonia More Likely To Develop Resistance With Use Of Ceftazidime-Avibactam Vs Ceftolozane-Tazobactam, Study Finds

Infectious Disease Advisor (7/23, Basilio) reports a study found “adult patients with multidrug-resistant (MDR) Pseudomonas aeruginosa bacteremia or pneumonia are more likely to develop resistance with the use of ceftazidime-avibactam vs ceftolozane-tazobactam.” Researchers found “that treatment-emergent resistance – defined as more than a 4-fold increase in baseline minimum inhibitory concentration – occurred in 40% of patients in the ceftazidime-avibactam group and 10% of those in the ceftolozane-tazobactam group.” The findings were published in Clinical Infectious Diseases.